Dr. Rongxin Chen 陈荣新
Chief Physician
Department of Medical Oncology (Liver Tumors), Zhongshan Hospital, Fudan University, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of liver diseases, with a focus on liver tumors. Expertise includes interventional therapy, minimally invasive therapy, and comprehensive treatment.
Dr. Chen is a Chief Physician and doctoral supervisor at Zhongshan Hospital, Fudan University. Clinical expertise includes the diagnosis and treatment of liver diseases, particularly liver tumors, using interventional, minimally invasive, and comprehensive therapies.
Name order: in Chinese the family name comes first (Chen Rongxin). Papers usually list the name as Rongxin Chen or Chen R.
Selected publications
110 papers on PubMed matched by name and affiliation; 21 as first or senior author since 2016. Most recent first- or senior-author papers:
- Oncogene, 2026 (senior author): Matrix stiffness drives HCC invasion and metastasis via interfering with TRIM21-mediated SCD1 ubiquitination. PubMed 42387055
- J Hepatocell Carcinoma, 2026 (senior author): Efficacy of Locoregional HAIC and Systemic Treatment for Treatment- Naive Unresectable Hepatocellulcar Carcinoma. PubMed 42226803
- J Gastrointest Oncol, 2025 (senior author): Revisiting the role of postoperative adjuvant transarterial chemoembolization in hepatocellular carcinoma: a propensity score matching analysis. PubMed 41522746
- FASEB J, 2025 (senior author): Matrix Stiffness Promotes Invasion and Metastasis of Hepatocellular Carcinoma via a New Mechanoresponsive SCD1/HMMR Pathway. PubMed 40497374
- Clin Exp Immunol, 2023 (senior author): Antinuclear antibody (ANA) status predicts immune-related adverse events in liver cancer patients undergoing anti-PD-1 therapy. PubMed 36966354
- Mol Ther, 2022 (senior author): An SCD1-dependent mechanoresponsive pathway promotes HCC invasion and metastasis through lipid metabolic reprogramming. PubMed 35358687
- Acad Radiol, 2021 (senior author): Hepatic Arterial Infusion Chemotherapy with Modified FOLFOX as an Alternative Treatment Option in Advanced Hepatocellular Carcinoma Patients with Failed or Unsuitability for Transarterial Chemoembolization. PubMed 33653656
- Oncogenesis, 2020 (senior author): Suppressing DRP1-mediated mitochondrial fission and mitophagy increases mitochondrial apoptosis of hepatocellular carcinoma cells in the setting of hypoxia. PubMed 32661251
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion